National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom

Feb-12

AUTHORS : Prof Irene Petersen, Upper Third Floor, UCL Medical School (Royal Free Campus), Rowland Hill Street, London NW3 2PF – Email: i.petersen@ucl.ac.uk – Profile: https://iris.ucl.ac.uk/iris/browse/profile?upi=IPETE57 – Contact is Philip Prah (details for study: MRC General Practice Research Framework) but it looks like he is now working at Phastar and I cannot find his contact details or more information about him.

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 21(2):161-9

DOI : 10.1002/pds.2213

National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study